+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "JAK Inhibitor"

Janus Kinase (JAK) Inhibitors Market Report 2025 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitors Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
JAK Inhibitors Market - Product Thumbnail Image

JAK Inhibitors Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
Janus Kinase (JAK) Inhibitors Market 2024-2028 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitors Market 2024-2028

  • Report
  • October 2024
  • 145 Pages
  • Global
From
Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 180 Pages
  • Global
From
From
From
From
From
From
From
From
Vitiligo Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Vitiligo Therapeutics - Global Strategic Business Report

  • Report
  • March 2025
  • 192 Pages
  • Global
From
From
Atopic Dermatitis Drugs - Global Strategic Business Report - Product Thumbnail Image

Atopic Dermatitis Drugs - Global Strategic Business Report

  • Report
  • March 2025
  • 179 Pages
  • Global
From
From
Loading Indicator

The JAK Inhibitor market is a subset of the larger Immune Disorders Drugs market. JAK Inhibitors are a type of drug used to treat a variety of immune-related disorders, such as rheumatoid arthritis, psoriasis, and Crohn's disease. These drugs work by blocking the activity of Janus kinase (JAK) enzymes, which are involved in the body's inflammatory response. JAK Inhibitors are typically taken orally, and are often used in combination with other medications. The JAK Inhibitor market is highly competitive, with a number of large pharmaceutical companies vying for market share. Some of the major players in the market include AbbVie, Pfizer, Novartis, and Johnson & Johnson. Other companies, such as Celgene, Merck, and Eli Lilly, are also active in the market. Show Less Read more